Firm Events
District Court vs. PTAB: Strategic Forum Selection in Life Sciences Patent Disputes
December 10, 2026 | 12:00 PM – 1:00 PM ET
On November 10, the Securities and Exchange Commission (SEC or Commission) released its enforcement results for the fiscal year ended September 30. The SEC’s Division of Enforcement (the Division) described a year focused on its core responsibilities of protecting investors, holding wrongdoers accountable, and safeguarding the integrity of the U.S. capital markets, while continuing to modernize its organization, processes, and technology. Here are the big themes.
In fiscal year 2026, the Commission filed 348 enforcement actions, including 235 standalone actions and 113 “follow-on” administrative proceedings that sought to bar or suspend individuals from certain securities market activities. It also instituted 13 trading suspensions in response to suspected manipulation involving the securities of Asia-based issuers.
The Commission obtained orders for monetary relief totaling $1.095 billion, composed of $752 million in disgorgement and prejudgment interest and $343 million in civil penalties. A court deemed $235 million of the disgorgement satisfied in a separate non-SEC action. The SEC also returned approximately $731 million to more than 250,000 harmed investors.
Compared with fiscal year 2025, standalone actions fell roughly 22% (from 303 to 235), while follow-on proceedings rose from 69 to 113. The $17.9 billion in monetary relief the SEC reported for fiscal year 2025 included Ponzi scheme judgments and amounts deemed satisfied in other proceedings; excluding those, the SEC reported about $2.7 billion ($1.4 billion in disgorgement and prejudgment interest and $1.3 billion in civil penalties), versus about $860 million this year on the same basis. Meanwhile, amounts returned to harmed investors rose from approximately $262 million to approximately $731 million, and whistleblower awards rose from approximately $60 million to more than $158 million.
Holding individuals accountable remains one of the Commission’s most effective deterrents. Two-thirds of the standalone enforcement actions filed this year included charges against at least one individual, including founders and CEOs, senior executives, and gatekeepers such as accountants, auditors, and investment adviser personnel. SEC Chairman Paul S. Atkins noted that “[e]nforcement actions and financial remedies are important measures of activity, but they are not the only or most telling measures,” emphasizing that the agency’s responsibility is to apply the law fairly and consistently.
The Division said its actions focused on serious and consequential violations of the federal securities laws, including fraud, market manipulation, insider trading, gatekeeper failures, and violations that compromise the integrity of disclosures and financial reporting. Several priority areas stood out:
The Division worked to increase its investigative and litigation capacity, address evolving market risks, and deliver more timely outcomes. Key organizational changes included:
The SEC called its whistleblower program an integral part of the Division’s work to detect and prosecute wrongdoing. Since the program’s inception, high-quality tips have led to more than $11 billion in financial remedies ordered by the Commission. In fiscal year 2026, the SEC received approximately 26,000 whistleblower tips and awarded more than $158 million to 65 individual whistleblowers, the highest number of individual whistleblowers since fiscal year 2023.
The SEC’s fiscal year 2026 results describe a more focused enforcement program that prioritizes consequential misconduct, individual accountability, and meaningful outcomes for investors, while the Division invests in the people, technology, and processes it expects to carry the program forward.
This just in
Firm Events
District Court vs. PTAB: Strategic Forum Selection in Life Sciences Patent Disputes
December 10, 2026 | 12:00 PM – 1:00 PM ET
Speaking Engagements
Performance on Trial: The Construction Manager’s Standard of Care Examined from All Angles
December 2, 2026 | 4:15 PM – 5:30 PM ET
The Hyatt Regency Huntington Beach
Huntington Beach, CA
Speaking Engagements
ACI’s 31st Annual Conference on Drug & Medical Device Litigation – 2026
December 2 – 3, 2026
New York Marriott Marquis
1535 Broadway, New York, NY 10036
Speaking Engagements
Fundamentals of Investment Adviser Regulation 2026
November 19, 2026 | 2:30 PM – 3:30 PM ET
PLI New York
1177 Avenue of the Americas, Entrance on 45th Street, New York, NY 10036